PHILADELPHIA--(BUSINESS WIRE)--May 15, 2006--Hemispherx Biopharma, Inc. (AMEX: HEB - News) today announced that it has procured the seasonal influenza vaccine it needs to execute a well-controlled (Placebo vs. Ampligen®) immunopotentiation clinical trial. This Phase II clinical trial will be conducted in Australia, where seasonal flu vaccination programs are already well underway for the fall/winter flu season.
